Skip to main content
Erschienen in:

14.11.2023 | Original article

Potential beneficial effect of IFN-β1a and ocrelizumab in people with MS during the COVID-19 pandemic

verfasst von: Stefan Todorović, Slobodan Vojinović, Dejan Savić, Dejan Aleksić, Miloš Danilović

Erschienen in: Acta Neurologica Belgica | Ausgabe 2/2024

Einloggen, um Zugang zu erhalten

Abstract

Background/Aim

Disease-modifying therapy (DMT) has led to added challenges in the management of people with multiple sclerosis (pwMS) during the COVID-19 era. It can reduce relapse in MS or slow down disease progression, but some DMTs can increased risk of infection. The aim of study was to evaluate risk and severity of COVID-19 in pwMS.

Methods

The examined group of pwMS were divided in group treated with IFN-β1a, group treated with ocrelizumab and untreated group. The examination included impact of age, gender, duration of MS, type of MS, vaccination status and Expanded Disability Status Scale (EDSS) on the risk and severity of COVID-19 infection. A diagnosis of COVID-19 in pwMS was confirmed by positive polymerase-chain-reaction (PCR) or antigen test.

Results

Out of 207 pwMS, 82 patients were treated with ocrelizumab, 63 with IFN-β1a, while 62 patients were untreated pwMS. The average duration of the MS was longer in the group of patients treated with ocrelizumab than in the group treated with IFN-β1a (p < 0.05). EDSS was higher in the ocrelizumab group compared to the other two groups (p < 0.001). Untreated (more often unvaccinated) had the same COVID frequency as ocrelizumab-treated (more vaccinated, but higher EDSS). The multivariate logistic regression model indicated that administration of IFN-β1a reduces the risk of COVID-19 infection (p = 0.001, OR = 0.381, 95% CI 0.602–0.160). The use of both DMTs, driven mainly by the IFN-β1a effect, reduces the risk of moderate and severe COVID-19 (p < 0.05, OR = 0.105, 95% CI 0.011–0.968).

Conclusion

This study provides evidence that IFN-β1a can reduce the frequency of COVID-19 infection and that two DMTs, driven mainly by the IFN-β1a effect, do not increase the risk of moderate/severe COVID-19.
Literatur
2.
Zurück zum Zitat MSIF (2020) Atlas of MS 2020: Mapping multiple sclerosis around the world. Key Epidemiology Findings. Multiple Sclerosis International Federation MSIF (2020) Atlas of MS 2020: Mapping multiple sclerosis around the world. Key Epidemiology Findings. Multiple Sclerosis International Federation
4.
Zurück zum Zitat Rotstein DL, Healy BC, Malik MT et al (2015) Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort. JAMA Neurol 72:152–158CrossRefPubMed Rotstein DL, Healy BC, Malik MT et al (2015) Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort. JAMA Neurol 72:152–158CrossRefPubMed
7.
Zurück zum Zitat Frieman M, Yount B, Heise M, Kopecky-Bromberg SA, Palese P, Baric RS (2017) Severe acute respiratory syndrome coronavirus ORF6 antagonizes STAT1 function by sequestering nuclear import factors on the rough endoplasmic reticulum/Golgi membrane. J Virol 81(18):9812–9824. https://doi.org/10.1128/JVI.01012-07 Frieman M, Yount B, Heise M, Kopecky-Bromberg SA, Palese P, Baric RS (2017) Severe acute respiratory syndrome coronavirus ORF6 antagonizes STAT1 function by sequestering nuclear import factors on the rough endoplasmic reticulum/Golgi membrane. J Virol 81(18):9812–9824. https://​doi.​org/​10.​1128/​JVI.​01012-07
8.
Zurück zum Zitat Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Montalban X, Rammohan KW, Selmaj K, Traboulsee A, Wolinsky JS, Arnold DL, Klingelschmitt G, Masterman D, Fontoura P, Belachew S, Chin P, Mairon N, Garren H, Kappos L (2017) OPERA I and OPERA II clinical investigators. ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med 376(3):221–234. https://doi.org/10.1056/NEJMoa1601277 Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Montalban X, Rammohan KW, Selmaj K, Traboulsee A, Wolinsky JS, Arnold DL, Klingelschmitt G, Masterman D, Fontoura P, Belachew S, Chin P, Mairon N, Garren H, Kappos L (2017) OPERA I and OPERA II clinical investigators. ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med 376(3):221–234. https://​doi.​org/​10.​1056/​NEJMoa1601277
12.
Zurück zum Zitat Chan JF, Yuan S, Kok KH, To KK, Chu H, Yang J, Xing F, Liu J, Yip CC, Poon RW, Tsoi HW, Lo SK, Chan KH, Poon VK, Chan WM, Ip JD, Cai JP, Cheng VC, Chen H, Hui CK, Yuen KY (2020) A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet 395(10223):514–523CrossRefPubMedPubMedCentral Chan JF, Yuan S, Kok KH, To KK, Chu H, Yang J, Xing F, Liu J, Yip CC, Poon RW, Tsoi HW, Lo SK, Chan KH, Poon VK, Chan WM, Ip JD, Cai JP, Cheng VC, Chen H, Hui CK, Yuen KY (2020) A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet 395(10223):514–523CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Xu PP, Tian RH, Luo S et al (2020) Risk factors for adverse clinical outcomes with COVID-19 in China: a multicenter, retrospective, observational study. Theranostics 10:6372–6383CrossRefPubMedPubMedCentral Xu PP, Tian RH, Luo S et al (2020) Risk factors for adverse clinical outcomes with COVID-19 in China: a multicenter, retrospective, observational study. Theranostics 10:6372–6383CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Iaffaldano P, Lucisano G, Manni A, Paolicelli D, Patti F, Capobianco M, Brescia Morra V, Sola P, Pesci I, Lus G, De Luca G, Lugaresi A, Cavalla P, Montepietra S, Maniscalco GT, Granella F, Ragonese P, Vianello M, Brambilla L, Totaro R, Toscano S, Malucchi S, Petracca M, Moiola L, Ferraro D, Lepore V, Mosconi P, Ponzio M, Tedeschi G, Comi G, Battaglia MA, Filippi M, Amato MP, Trojano M (2022) Italian MS Register. Risk of getting COVID-19 in people with multiple sclerosis: a case–control study. Neurol Neuroimmunol Neuroinflamm 9(2):e1141. https://doi.org/10.1212/NXI.0000000000001141 Iaffaldano P, Lucisano G, Manni A, Paolicelli D, Patti F, Capobianco M, Brescia Morra V, Sola P, Pesci I, Lus G, De Luca G, Lugaresi A, Cavalla P, Montepietra S, Maniscalco GT, Granella F, Ragonese P, Vianello M, Brambilla L, Totaro R, Toscano S, Malucchi S, Petracca M, Moiola L, Ferraro D, Lepore V, Mosconi P, Ponzio M, Tedeschi G, Comi G, Battaglia MA, Filippi M, Amato MP, Trojano M (2022) Italian MS Register. Risk of getting COVID-19 in people with multiple sclerosis: a case–control study. Neurol Neuroimmunol Neuroinflamm 9(2):e1141. https://​doi.​org/​10.​1212/​NXI.​0000000000001141​
19.
Zurück zum Zitat Mallucci G, Zito A, Baldanti F et al (2021) Safety of disease-modifying treatments in SARS-CoV-2 antibody-positive multiple sclerosis patients. MultSclerRelatDisord 49:102754 Mallucci G, Zito A, Baldanti F et al (2021) Safety of disease-modifying treatments in SARS-CoV-2 antibody-positive multiple sclerosis patients. MultSclerRelatDisord 49:102754
20.
Zurück zum Zitat Fernandes PM, O’Neill M, Kearns PKA et al (2020) Impact of the first COVID-19 pandemic wave on the Scottish Multiple Sclerosis Register population. Wellcome Open Res 5:276CrossRefPubMedPubMedCentral Fernandes PM, O’Neill M, Kearns PKA et al (2020) Impact of the first COVID-19 pandemic wave on the Scottish Multiple Sclerosis Register population. Wellcome Open Res 5:276CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Costabile T, Carotenuto A, Lavorgna L, Borriello G, Moiola L, Inglese M, Petruzzo M, Trojsi F, Ianniello A, Nozzolillo A, Cellerino M, Boffa G, Rosa L, Servillo G, Moccia M, Bonavita S, Filippi M, Lanzillo R, Brescia Morra V, Petracca M (2020) COVID-19 pandemic and mental distress in multiple sclerosis: Implications for clinical management. Eur J Neurol. 28(10):3375–3383. https://doi.org/10.1111/ene.14580 Costabile T, Carotenuto A, Lavorgna L, Borriello G, Moiola L, Inglese M, Petruzzo M, Trojsi F, Ianniello A, Nozzolillo A, Cellerino M, Boffa G, Rosa L, Servillo G, Moccia M, Bonavita S, Filippi M, Lanzillo R, Brescia Morra V, Petracca M (2020) COVID-19 pandemic and mental distress in multiple sclerosis: Implications for clinical management. Eur J Neurol. 28(10):3375–3383. https://​doi.​org/​10.​1111/​ene.​14580
22.
Zurück zum Zitat Australian National COVID-19 Clinical Evidence Taskforce. Australian guidelines for the clinical care of people with COVID-19, Version 16. Australian National COVID-19 Clinical Evidence Taskforce; 2020 [cited 2020 August 2]. Available from https://covid19evidence.net.au/ Australian National COVID-19 Clinical Evidence Taskforce. Australian guidelines for the clinical care of people with COVID-19, Version 16. Australian National COVID-19 Clinical Evidence Taskforce; 2020 [cited 2020 August 2]. Available from https://​covid19evidence.​net.​au/​
24.
Zurück zum Zitat Moss BP, Mahajan KR, Bermel RA, Hellisz K, Hua LH, Hudec T, Husak S, McGinley MP, Ontaneda D, Wang Z, Weber M, Tagliani P, Cárdenas-Robledo S, Zabalza A, Arrambide G, Carbonell-Mirabent P, Rodríguez-Barranco M, Sastre-Garriga J, Tintore M, Montalban X, Douglas M, Ogbuokiri E, Aravidis B, Cohen JA, Mowry EM, Fitzgerald KC. (2020) Multiple sclerosis management during the COVID-19 pandemic. Mult Scler. 26(10):1163–1171. https://doi.org/10.1177/1352458520948231 Moss BP, Mahajan KR, Bermel RA, Hellisz K, Hua LH, Hudec T, Husak S, McGinley MP, Ontaneda D, Wang Z, Weber M, Tagliani P, Cárdenas-Robledo S, Zabalza A, Arrambide G, Carbonell-Mirabent P, Rodríguez-Barranco M, Sastre-Garriga J, Tintore M, Montalban X, Douglas M, Ogbuokiri E, Aravidis B, Cohen JA, Mowry EM, Fitzgerald KC. (2020) Multiple sclerosis management during the COVID-19 pandemic. Mult Scler. 26(10):1163–1171. https://​doi.​org/​10.​1177/​1352458520948231​
26.
Zurück zum Zitat Monk PD, Marsden RJ, Tear VJ, Brookes J, Batten TN, Mankowski M, Gabbay FJ, Davies DE, Holgate ST, Ho LP, Clark T, Djukanovic R, Wilkinson TMA (2021) Inhaled Interferon Beta COVID-19 Study Group. Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Respir Med 9(2):196–206. https://doi.org/10.1016/S2213-2600(20)30511-7 Monk PD, Marsden RJ, Tear VJ, Brookes J, Batten TN, Mankowski M, Gabbay FJ, Davies DE, Holgate ST, Ho LP, Clark T, Djukanovic R, Wilkinson TMA (2021) Inhaled Interferon Beta COVID-19 Study Group. Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Respir Med 9(2):196–206. https://​doi.​org/​10.​1016/​S2213-2600(20)30511-7
29.
Zurück zum Zitat Sosa JP, Ferreira Caceres MM, Ross Comptis J, Quiros J, Príncipe-Meneses FS, Riva-Moscoso A, Belizaire MP, Malanyaon FQ, Agadi K, Jaffery SS, Sahajwani J, Arshia A, Senatus A, Verdecia G, Akano L, Razzack AA, Salam S, Gadamidi VK, Marian S (2021) Effects of interferon beta in COVID-19 adult patients: systematic review. Infect Chemother 53(2):247–260. https://doi.org/10.3947/ic.2021.0028CrossRefPubMedPubMedCentral Sosa JP, Ferreira Caceres MM, Ross Comptis J, Quiros J, Príncipe-Meneses FS, Riva-Moscoso A, Belizaire MP, Malanyaon FQ, Agadi K, Jaffery SS, Sahajwani J, Arshia A, Senatus A, Verdecia G, Akano L, Razzack AA, Salam S, Gadamidi VK, Marian S (2021) Effects of interferon beta in COVID-19 adult patients: systematic review. Infect Chemother 53(2):247–260. https://​doi.​org/​10.​3947/​ic.​2021.​0028CrossRefPubMedPubMedCentral
30.
Zurück zum Zitat Maniscalco GT, Manzo V, Ferrara AL, Perrella A, Di Battista M, Salvatore S, Graziano D, Viola A, Amato G, Moreggia O, Di Giulio Cesare D, Barbato S, Servillo G, Longo K, Di Giovanni M, Scarpati B, Muggianu SM, Longo G, Russo G, Andreone V, De Rosa V (2022) Interferon Beta-1a treatment promotes SARS-CoV-2 mRNA vaccine response in multiple sclerosis subjects. MultSclerRelatDisord 58:103455. https://doi.org/10.1016/j.msard.2021.103455 Maniscalco GT, Manzo V, Ferrara AL, Perrella A, Di Battista M, Salvatore S, Graziano D, Viola A, Amato G, Moreggia O, Di Giulio Cesare D, Barbato S, Servillo G, Longo K, Di Giovanni M, Scarpati B, Muggianu SM, Longo G, Russo G, Andreone V, De Rosa V (2022) Interferon Beta-1a treatment promotes SARS-CoV-2 mRNA vaccine response in multiple sclerosis subjects. MultSclerRelatDisord 58:103455. https://​doi.​org/​10.​1016/​j.​msard.​2021.​103455
35.
Zurück zum Zitat Alroughani R, Inshasi JS, Al-Hashel J, Alkhaboury J, Alsalti A, Suwaidi RA, Hassino LH, Ahmed SF (2022) Incidence, severity, outcomes, and risk factors of COVID-19 in multiple sclerosis: an observational study in the Middle East. Mult Scler Relat Disord 59:103579. https://doi.org/10.1016/j.msard.2022.103579 Alroughani R, Inshasi JS, Al-Hashel J, Alkhaboury J, Alsalti A, Suwaidi RA, Hassino LH, Ahmed SF (2022) Incidence, severity, outcomes, and risk factors of COVID-19 in multiple sclerosis: an observational study in the Middle East. Mult Scler Relat Disord 59:103579. https://​doi.​org/​10.​1016/​j.​msard.​2022.​103579
36.
Zurück zum Zitat Sormani MP, De Rossi N, Schiavetti I, Carmisciano L, Cordioli C, Moiola L, Radaelli M, Immovilli P, Capobianco M, Trojano M, Zaratin P, Tedeschi G, Comi G, Battaglia MA, Patti F, Salvetti M; Musc-19 Study Group (2021) Disease-modifying therapies and coronavirus disease 2019 severity in multiple sclerosis. Ann Neurol 89(4):780–789. https://doi.org/10.1002/ana.26028 Sormani MP, De Rossi N, Schiavetti I, Carmisciano L, Cordioli C, Moiola L, Radaelli M, Immovilli P, Capobianco M, Trojano M, Zaratin P, Tedeschi G, Comi G, Battaglia MA, Patti F, Salvetti M; Musc-19 Study Group (2021) Disease-modifying therapies and coronavirus disease 2019 severity in multiple sclerosis. Ann Neurol 89(4):780–789. https://​doi.​org/​10.​1002/​ana.​26028
40.
Zurück zum Zitat Inshasi J, Alroughani R, Al-Asmi A, Alkhaboury J, Alsalti A, Boshra A, Canibano B, Deleu D, Ahmed SF, Shatila A, Thakre M (2021) Expert consensus and narrative review on the management of multiple sclerosis in the Arabian Gulf in the COVID-19 era: focus on disease-modifying therapies and vaccination against COVID-19. NeurolTher. 10(2):539–555. https://doi.org/10.1007/s40120-021-00260-5 Inshasi J, Alroughani R, Al-Asmi A, Alkhaboury J, Alsalti A, Boshra A, Canibano B, Deleu D, Ahmed SF, Shatila A, Thakre M (2021) Expert consensus and narrative review on the management of multiple sclerosis in the Arabian Gulf in the COVID-19 era: focus on disease-modifying therapies and vaccination against COVID-19. NeurolTher. 10(2):539–555. https://​doi.​org/​10.​1007/​s40120-021-00260-5
Metadaten
Titel
Potential beneficial effect of IFN-β1a and ocrelizumab in people with MS during the COVID-19 pandemic
verfasst von
Stefan Todorović
Slobodan Vojinović
Dejan Savić
Dejan Aleksić
Miloš Danilović
Publikationsdatum
14.11.2023
Verlag
Springer International Publishing
Erschienen in
Acta Neurologica Belgica / Ausgabe 2/2024
Print ISSN: 0300-9009
Elektronische ISSN: 2240-2993
DOI
https://doi.org/10.1007/s13760-023-02421-9

Kompaktes Leitlinien-Wissen Neurologie (Link öffnet in neuem Fenster)

Mit medbee Pocketcards schnell und sicher entscheiden.
Leitlinien-Wissen kostenlos und immer griffbereit auf ihrem Desktop, Handy oder Tablet.

Neu im Fachgebiet Neurologie

Schlaganfall oder Schlaganfall-Imitator?

Ein breites Spektrum von Erkrankungen kann einen Schlaganfall vortäuschen. Bei der notwendigen schnellen Unterscheidung zwischen solchen „stroke mimics“ und echten Schlaganfällen können einige klinische Faktoren und Symptome unterstützend herangezogen werden. 

Ein pulverisierter Plastiklöffel im Gehirn

Das menschliche Gehirn besteht zu etwa 0,5% aus Nanoplastik – Tendenz weiter steigend. Nach Resultaten eine Autopsiestudie reichert sich Plastik im Gehirn 10- bis 30-fach stärker an als in anderen Organen – mit bislang noch völlig unklaren Folgen.

Schlaganfall durch wandernde A. carotis interna

Die Thrombolyse nützte nichts, vielmehr war eine Teilresektion des Zungenbeins nötig: Es hatte eine verlagerte Carotis interna komprimiert und so bei einem älteren Mann einen Schlaganfall ausgelöst. Per Bildgebung lässt sich eine solche Ursache manchmal nur schwer nachweisen.

Epileptischer Anfall nach Darmreinigung

Die Darmreinigung vor einer Koloskopie führte einen älteren Mann auf die Intensivstation: Seine Natriumwerte waren durch die Prozedur so gesunken, dass er Bewusstseinstrübungen und Krampfanfälle entwickelte.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.